|
| Home : Alligator Bioscience AB (publ) Interim Report January-March 2019 |
|
Apr 17
2019 |
Alligator Bioscience AB (publ) Interim Report January-March 2019 |
|
STOCKHOLM, April 17, 2019 /PRNewswire/ -- Significant events January-March First patient dosed in Phase I clinical study of ATOR-1015. New preclinical data presented demonstrating strong anti-tumor effects for the 4-1BB antibody ATOR-1017. Alligator Bioscience launched RUBY™, a novel... |
|
|
|
| Source:https://www.prnewswire.com:443/news-releases/alligator-bioscience-ab-publ-interim-report-january-march-2019-300833596.html |
| |
|
Related News
|
» Notice to Annual General Meeting in Hansa Biopharma AB (publ)
» Ericsson and Swisscom in European Commercial 5G First
|
|
|
